Lorlatinib acetate

Overview

Lorlatinib (PF-06463922) acetate is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor with anticancer activity. Lorlatinib acetate has K i s of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK L1196M , respectively. Lorlatinib acetate targets to EML4-ALK, and inhibits ALK phosphorylation with IC 50 s of 15-43 nM (ALK L1196 ), 14-80 nM (ALK G1269A ), 38-50 nM (ALK 1151Tins ), 77-113 nM (ALK G1202R ), respectively.

Application

Products | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > ROS Kinase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-135509
• CAS No.: 1924207-18-0
• Molecular Formula: C23H23FN6O4
• Molecular Weight: 466.46
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source